Keywords: gsk, shares, slide, after, avandia, linked, cv
GSK shares slide 5.1% after Avandia linked to CV death risk; firm likely to cut guidance
Article | 28 May 2007
New study data has linked GlaxoSmithKline's Avandia (rosiglitazone) to significant risk of heart attack and, when the meta-analysis results were ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
